Effects of Age and Obesity on Brain Insulin Sensitivity

Obesity Clinical Trial

— Aging  

Official title:

Insulinsensitivität Des Menschlichen Zentralnervensystems Mit Fortschreitendem Alter: Kernspintomographische Untersuchung Mit Intranasaler Gabe Von Insulin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04372849
• Other study ID #: 837/2016BO2
• Status: Completed
• Phase: N/A
• Start date: April 28, 2017
• Est. completion date: March 1, 2020

Study information

• Verified date: April 2020
• Source: University Hospital Tuebingen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obesity and especially type 2 diabetes (T2D) increases the risk of neurocognitive dysfunctions including adverse effects on brain structure and function. Recent evidence from clinical studies have shown that T2D almost doubles the risk for dementia. As the population gets older, age-related chronic diseases, as T2D, become more prevalent. Scientific evidence is emerging that there are several links between metabolic and neurocognitive functions. Impaired insulin action (i.e. insulin resistance), the main hallmark of T2D, has been suggested as a likely shared common pathophysiological mechanism. However, the neural processes that determine how insulin resistance is are connected to the onset and progression of T2D and dementia remain unclear. In this context, the overall aim is to study brain insulin resistance to disentangle age-related and obesity related brain insulin resistance in healthy normal and overweight/obese persons at the age of 20 to 70 years . To this end, the investigators will assess brain insulin action using intranasal insulin/placebo during functional Magnetic Resonance Imaging (fMRI). Additionally, structural changes and cognitive processes will be assessed as secondary variables.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: March 1, 2020
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Body-Mass Index (BMI) between 19-35 kg/m2

• HbA1c =6.0%

• normal glucose tolerance during 75g oral glucose tolerance test (OGTT)

Exclusion Criteria:

• Not removable metal parts in or on the body

• manifest cardiovascular disease

• claustrophobia

• recent surgery (less than 3 months)

• Simultaneous participation in other studies

• Acute disease or infection within the last 4 weeks

• neurological and psychiatric disorders

• treatment with centrally acting drugs

• hemoglobin Hb <13g / dl

• Hypersensitivity to any of the substances used

Related Conditions & MeSH terms

• Insulin Resistance
• Obesity

Intervention

Other:
• Human nasal insulin
single dose of 160 U of human insulin as nasal spray
• Placebo
Single dose of placebo solution as nasal spray

Locations

Country	Name	City	State
Germany	University of Tuebingen, Department of Internal Medicine IV	Tübingen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Brain insulin sensitivity in different age,weight and sex groups	fMRI measurement will be performed before and after administration of 160 U of human insulin or placebo as nasal spray. Changes in regional brain activity will be quantified by cerebral blood flow and blood oxygenation dependent (BOLD) signal to assess regional brain insulin sensitivity. Brain insulin sensitivity will be compared between eight groups (young normal weight men and women, young overweight/obese men and women, old normal weight men and women, old overweight/obese men and women). Persons are categorized into normal weight and overweight/obese based on the Body Mass Index (BMI). Age groups are build based on a median split.	30 minutes after administration of nasal insulin
Secondary	Whole-body insulin sensitivity	Insulin sensitivity will be estimated from a frequent-sampling 75 g oral glucose tolerance test (oGTT) using the Matsuda formula. Correlation of regional brain insulin sensitivity by intranasal insulin will be performed with whole-body insulin sensitivity based on oGTT. Changes in regional cerebral blood flow from before to after intranasal insulin administration will be assessed by functional magnetic resonance imaging (fMRI).	2 hours
Secondary	Correlation with autonomous nervous system activity	Correlation of the change in regional brain insulin sensitivity by intranasal insulin with the simultaneous change of the autonomous nervous system (measured by heart rate variability).	10 - 150 minutes post nasal spray
Secondary	Correlation with cognitive function	Correlation of the change in regional brain insulin sensitivity by intranasal insulin with cognitive measures addressed by neuropsychological testing.	1 hours
Secondary	Response to food cues	Brain response to food cues assessed by functional magnetic resonance imaging. Food cues will be rated for palatability on a visual analogue scale.	20 minutes